Telomir pharmaceuticals inc TELO.US 總覽分析
TELO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
TELO 近期報酬表現
3.19%
Telomir pharmaceuticals inc
3.56%
同產業平均
1.47%
S&P500
與 TELO 同產業的標的表現
- CAMP Camp4 therapeutics corp價值 -趨勢 1 分波段 2 分籌碼 2 分股利 1 分查看更多
TELO 公司資訊
Telomir Pharmaceuticals Inc. Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson's disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer's disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.